Adventist Health Howard Memorial | |
1 Marcela Dr, Willits, California 95490 | |
(707) 456-3031 | |
Name | Adventist Health Howard Memorial |
---|---|
Type | Critical Access Hospital |
Location | 1 Marcela Dr, Willits, California |
Ownership | Voluntary non-profit - Church |
Emergency Services | Yes |
Medicare ID (CCN) | 051310 |
NPI Number | 1083602122 |
Organization Name | WILLITS HOSPITAL INC. |
Doing Business As | ADVENTIST HEALTH HOWARD MEMORIAL |
Address | 1 Marcela Drive, Willits, CA 95490 |
Hospital Type | General Acute Care Hospital - Critical Access |
Phone Number | 707-459-6801 |
News Archive
Phagelux, Inc., a leading anti-bacterial company, is pleased to announce the purchase of the key assets of Scithera Microbial Technologies, Ltd., headquartered in Wuhan China, a pioneer in the research and development of lysin solutions for pathogen control in the field of human health.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
A new NPR/Robert Wood Johnson Foundation/Harvard T.H. Chan School of Public Health poll finds that more than six in ten people living in the U.S. (62%) are concerned about their future health. Nearly four in ten (39%) said that they had one or more negative childhood experiences that they believe had a harmful impact on their adult health.
Epocrates, Inc., today announced its top-ranked clinical reference application for the iPhone® and iPod® touch devices will be customized for the new iPad™ computer tablet. The iPad is already receiving a warm reception from the healthcare industry with nearly 20 percent of clinicians expressing plans to purchase in an Epocrates survey conducted days after the Apple announcement.
› Verified 2 days ago
NPI Number | 1356339543 |
Organization Name | WILLITS HOSPITAL INC. |
Doing Business As | ADVENTIST HEALTH HOWARD MEMORIAL |
Address | 1 Marcela Drive, Willits, CA 95490 |
Hospital Type | General Acute Care Hospital - Critical Access |
Phone Number | 707-459-6801 |
News Archive
Phagelux, Inc., a leading anti-bacterial company, is pleased to announce the purchase of the key assets of Scithera Microbial Technologies, Ltd., headquartered in Wuhan China, a pioneer in the research and development of lysin solutions for pathogen control in the field of human health.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
A new NPR/Robert Wood Johnson Foundation/Harvard T.H. Chan School of Public Health poll finds that more than six in ten people living in the U.S. (62%) are concerned about their future health. Nearly four in ten (39%) said that they had one or more negative childhood experiences that they believe had a harmful impact on their adult health.
Epocrates, Inc., today announced its top-ranked clinical reference application for the iPhone® and iPod® touch devices will be customized for the new iPad™ computer tablet. The iPad is already receiving a warm reception from the healthcare industry with nearly 20 percent of clinicians expressing plans to purchase in an Epocrates survey conducted days after the Apple announcement.
› Verified 2 days ago
Able to receive lab results electronically | Not Available |
Able to track patients' lab results, tests, and referrals electronically between visits | Not Available |
News Archive
Phagelux, Inc., a leading anti-bacterial company, is pleased to announce the purchase of the key assets of Scithera Microbial Technologies, Ltd., headquartered in Wuhan China, a pioneer in the research and development of lysin solutions for pathogen control in the field of human health.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
A new NPR/Robert Wood Johnson Foundation/Harvard T.H. Chan School of Public Health poll finds that more than six in ten people living in the U.S. (62%) are concerned about their future health. Nearly four in ten (39%) said that they had one or more negative childhood experiences that they believe had a harmful impact on their adult health.
Epocrates, Inc., today announced its top-ranked clinical reference application for the iPhone® and iPod® touch devices will be customized for the new iPad™ computer tablet. The iPad is already receiving a warm reception from the healthcare industry with nearly 20 percent of clinicians expressing plans to purchase in an Epocrates survey conducted days after the Apple announcement.
› Verified 2 days ago
Adventist Health Howard Memorial Critical Access Hospital Location: 1 Marcela Dr, Willits, California 95490 Phone: (707) 456-3031 |